<?xml version="1.0" encoding="UTF-8"?>
<p>A central review of the pathological diagnosis was carried out for 45 enrolled patients, and all were confirmed as having cyclin D1‐positive MCL, although 1 patient was diagnosed as having CD5‐negative MCL. Although CD5 positivity was defined as an eligibility criterion in this study, the Central Pathology Review Committee decided that this patient was pathologically eligible, as CD5 negativity was not unequivocally confirmed by other techniques, including flow cytometry.</p>
